


THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER –
ARTHUR G. JAMES CANCER HOSPITAL AND RICHARD J. SOLOVE RESEARCH INSTITUTE

2022

Accomplishments Report

TOWARD A CANCER-FREE WORLD




The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER

2022 OSUCCC – JAMES ANNUAL SCIENTIFIC MEETING

On the Cover



Titled “Ball of Fire,” the image on the cover is a 3-dimensional organoid that was photographed at the Campus Microscopy & Imaging Facility in Ohio State’s Biomedical Research Tower. An organoid is a small mass of tissue crafted from a person’s tumor cells, or by growing stem cells in the laboratory, to imitate the structure and functions of human tissues and organs for use in studying diseases such as cancer.

This image was submitted by **Shivam Priya, PhD**, a postdoctoral researcher at the OSUCCC – James, for the Art of Cancer Research competition held in conjunction with the 2022 OSUCCC – James

Annual Scientific Meeting. Dr. Priya’s research focuses on molecular and cell biology, particularly signaling pathways in cancer, such as receptor tyrosine kinases, MAPK (mitogen-activated protein kinases) and apoptosis, or naturally programmed cell death. Dr. Priya, who earned his PhD at Integral University in India, has presented his work at several national and international conferences, seminars and workshops.

Read more about advances in organoid development at Ohio State on page 11.

Ormiston awarded Michael L. Hess Prize



Kate Ormiston, PhD (right), a postdoctoral researcher at the OSUCCC – James, accepts the 2022 Michael L. Hess Prize for Cancer Research Excellence from OSUCCC Deputy Director **Peter Shields, MD**, at the 2022 OSUCCC – James Annual Scientific Meeting. The annual Hess Prize, made possible by the generosity of Irene Levine and Lee Hess, recognizes the top poster submission among all categories at this meeting as chosen by the poster awards committee. Ormiston’s entry was titled “Abrupt Involution of Mouse Mammary Gland Leads to Inflammatory Systemic Changes Along With Mammary-Specific Pro-Tumorigenic Changes Increasing the Risk of Breast Cancer.”

Renowned surgical oncologist Dr. William B. Farrar retires as CEO of The James



William B. Farrar, MD, a surgical oncologist at Ohio State for nearly five decades who also had served as CEO of The James for the past few years, retired June 30, 2022. A long-time leader who is beloved by patients and respected by colleagues, Dr. Farrar was the first surgical oncology fellow at Ohio State and the last medical trainee of the late Arthur G. James, MD – the hospital’s namesake – known to be working in 2022. (Dr. James died in 2001.)

During his 46-year tenure at the OSUCCC – James, Dr. Farrar performed more than 20,000 surgeries on patients with nearly every kind of malignancy except brain cancer. Later in his career, he began specializing in breast cancer care and conducting research and clinical trials. To read more about his career, visit go.osu.edu/FarrarLegacy. **David E. Cohn, MD, MBA**, chief medical officer at The James, became interim CEO on July 1, 2022.

THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER –
ARTHUR G. JAMES CANCER HOSPITAL
AND RICHARD J. SOLOVE RESEARCH
INSTITUTE (OSUCCC – JAMES)
LEADERSHIP



DAVID E. COHN, MD, MBA
Interim Chief Executive Officer and
Chief Medical Officer,
James Cancer Hospital and Solove
Research Institute



RAPHAEL E. POLLOCK, MD, PhD, FACS
Director, The Ohio State University
Comprehensive Cancer Center

To read more about
OSUCCC – James leadership,
visit cancer.osu.edu/leaders.

2022 Accomplishments Report:

TARA KUISICK
Editor

BOB HECKER
AMANDA HARPER
Writers

KEY FACTS 2022

#ChooseTheJames

The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER

Who we are

The OSUCCC – James is a unique matrix cancer center that features:



Freestanding cancer hospital



A Cancer Center Designated by the
National Cancer Institute



Nationally ranked
academic health center



On the campus of one of the
nation's largest public universities,
with seven health sciences colleges

Vision

To create a cancer-free world, one
person, one discovery at a time.

Mission


To eradicate cancer from individuals' lives
by creating knowledge and integrating
groundbreaking research with excellence
in education and patient-centered care.

News and Awards

cancer.osu.edu/news

cancer.osu.edu/awards

The James Cancer Network



Philanthropy

\$60.5M+ in FY22

Our people

5,260 faculty
and staff

254 volunteers



Exceptional Research



NCI **"Exceptional"** rating in past three reviews


One of only 54 NCI Comprehensive Cancer Centers

\$64.2M in total NCI grant funding

23 NCI grants awarded in 2022

Research centers

- Pelotonia Institute for Immuno-Oncology cancer.osu.edu/PIIO
- Center for Cancer Engineering cancer.osu.edu/CCE
- Drug Development Institute cancer.osu.edu/DDI
- Center for Cancer Metabolism cancer.osu.edu/CCM
- Center for Cancer Health Equity cancer.osu.edu/CCHE
- Center for Tobacco Research cancer.osu.edu/CTR
- Center for Cancer Mentoring, Education, Leadership and Oncology-Related Training (CAMELOT) cancer.osu.edu/CAMELOT





1,700+ cancer researchers

5 interactive research programs

Funded Principal Investigators work in
11 of 15 Ohio State colleges

825 research publications

18 shared resources



Clinical trials

- NCI's National Clinical Trials Network Lead Academic Participating Site
- One of only a few funded by NCI to conduct phase I and II clinical trials on novel anticancer agents provided by the NCI
- **687** clinical trials available
- **152** clinical trials opened
- **65K+** patients on Total Cancer Care® protocol

Collaborations

Co-founder



nccn.org



oriencancer.org

Member



bigtencrc.org



adcc.org



Excellence in Patient Care



- **3rd-largest cancer hospital** in the U.S.
- **200+** cancer physician subspecialists
- **Magnet® recognition** for excellence in nursing
- **1st hospital system** in the U.S. to use digital pathology for primary diagnosis
- **1st freestanding cancer hospital** in the midwest
- **24 consecutive years** nationally ranked
- **10** outpatient locations
- **15** mammography locations

By the numbers

356 inpatient beds

~14K inpatient stays

~67K infusions

19 ORs

732K+ outpatient visits

54K+ radiation procedures

9 LINACs + Gamma Knife

~12K surgeries

43K+ mammograms

Survivorship

- Hundreds of JamesCare for Life programs
- Patient support throughout continuum of care
- Cancer education
- Managing life with cancer; including the Cancer and Aging Resiliency (CARE) Clinic, fertility preservation, adolescent and young adult programs and more
- Mental, emotional, physical and spiritual well-being
- Caregiver, children & peer support
- Hope's Boutique



Patient experience

7 straight Press Ganey Guardian of Excellence Awards®

4 straight Press Ganey Pinnacle of Excellence Awards®



A QUALITY PROGRAM
of the AMERICAN COLLEGE
OF SURGEONS



Connect with us

Make an appointment

At a location or with The James Cancer Diagnostic Center:
800-293-5066

Refer a patient

- Patient Referral Center at 800-293-5066
- cancer.osu.edu/refer
- Ohio State CareLink referral web portal at wexnermedical.osu.edu/carelink

Find a clinical trial

cancer.osu.edu/clinicaltrials

Sign up to receive publications

cancer.osu.edu/pubs

Choose TheJames

The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER

Cancer website

cancer.osu.edu

Blog

cancer.osu.edu/blog



Podcast

cancer.osu.edu/podcast



Health & Discovery website

health.osu.edu/health/cancer

Social media

cancer.osu.edu/socialmedia



Pelotonia

Pelotonia community raised

\$21.8M+ in 2022

100% of funds

raised go toward cancer research at the OSUCCC – James

Learn more at go.osu.edu/2022PelotoniaImpact

\$258M+

raised in the first 14 years

2nd largest

cycling fundraising event in the country




Join us! pelotonia.org



Highlights of OSUCCC – James prominent cancer research studies

Flu vaccine may become new melanoma treatment



Carlo Contreras, MD

The flu vaccine could double as a breakthrough treatment for advanced melanoma, according to Ohio State research. Skin cancer specialists at the OSUCCC – James are conducting an immunotherapy study that may lead to a new use for influenza vaccination through a more targeted method of injection.

Carlo Contreras, MD, associate professor in the Division of Surgical

Oncology at Ohio State and member of the Translational Therapeutics Program at the OSUCCC – James, explains that, instead of administering the annual flu vaccine in a patient's arm, clinicians would inject it directly into the melanoma so it can recognize and kill cancer cells.

Two titans of cancer research honored at memorial scientific symposium

Medical scientists from the United States, Germany, Finland and Spain lectured on cancer-related topics held dear by two titans of cancer research — **Clara D. Bloomfield, MD**, and **Albert de la Chapelle, MD, PhD** — at a memorial symposium in their honor at the OSUCCC – James, where they played key leadership roles from 1997 until they died only eight months apart in 2020.



The symposium, which took place in June 2022 on Ohio State's campus and was livestreamed to a wider audience, was a gathering of friends, colleagues and trainees of these two internationally renowned scientists, whose groundbreaking studies in hematologic malignancies and human cancer genetics helped change the landscape of science-based cancer care.

Raphael E. Pollock, MD, PhD, FACS, director of The Ohio State University Comprehensive Cancer Center, said their contributions to a broad spectrum of cancer issues "is matched only by their remarkable mentoring impact and development of cancer programs that continue to thrive on the basis of what they accomplished."

Study reveals male sex hormones are new targets for cancer immunotherapy



Zihai Li, MD, PhD

Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking discrepancies in incidence, progression, response to treatment and survival outcomes depending on their sex. In almost all cases, male patients have worse prognoses and outcomes, a phenomenon that has puzzled the scientific community

for decades. A study published in the journal *Science Immunology* and led by researchers at the Pelotonia Institute for Immuno-Oncology (PIIO) at the OSUCCC – James examined the differences in intratumoral immune responses between male and female cancers of non-reproductive origin. PIIO Founding Director **Zihai Li, MD, PhD**, was senior corresponding author for the study, which reported a landmark finding that describes how male sex hormones called androgens contribute to cancer-related sex bias via the modulation of CD8+ T cells.

Discovery could 'revolutionize' understanding of aggressive cancer growth and spread



Deliang Guo, PhD

New data show that ammonia, typically known as a waste byproduct from protein degradation that is excreted from the human body through urine, plays a key role in fueling the rapid growth of certain aggressive forms of cancer. Representing the culmination of more than a decade of laboratory research, an OSUCCC – James team

reported findings that ammonia is not a waste molecule but plays a critical role in activating fat production in cancer cells, promoting cancer growth and spread. Their findings appeared in the journal *Nature Metabolism*.

Deliang Guo, PhD, professor in the Department of Radiation Oncology at Ohio State and member of the Translational Therapeutics Program at the OSUCCC – James, was senior author; **Chunming Cheng, PhD**, a research scientist in Radiation Oncology, was first author.

Highlights of key grants

Researchers awarded NCI grant to help boost clinical trial accrual of underrepresented populations



Electra Paskett, PhD, MSPH



Cheryl Lee, MD

Researchers at the OSUCCC – James received a five-year, \$3.5 million grant from the National Cancer Institute (NCI) to support Ohio State's

“Connecting Underrepresented Populations to Clinical Trials (CUSP2CT)” project, which is designed to increase referral and accrual of racial/ethnic minorities to cancer prevention, control and treatment trials at the OSUCCC – James. PIs for the grant are **Electra Paskett, PhD, MSPH**, and **Cheryl Lee, MD**. Dr. Paskett is professor and director of the Division of Cancer Prevention and Control at Ohio State. At the OSUCCC – James, she is associate director for population sciences and community outreach, and director of the Center for Cancer Health Equity. Dr. Lee is professor and chair of the Department of Urology at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James.

Scientists land NCI grant to develop therapy against rare large B-cell lymphoma



Lapo Alinari, MD, PhD

The NCI awarded a five-year, \$2.9 million grant to help researchers at the OSUCCC – James study a rare form of large B-cell lymphoma (LBCL) and develop a targeted therapy for patients with this currently incurable cancer. PI is **Lapo Alinari, MD, PhD**, assistant professor in the Division of Hematology at Ohio State and member of the Leukemia Research

Program at the OSUCCC – James. In their project abstract, Dr. Alinari and colleagues state that patients with LBCL that overexpresses the c-Myc protein have a significantly worse prognosis than patients with the cMyc-negative form of the disease – highlighting the need for novel therapeutic strategies.

Ohio State receives funding to study novel biodosimetry solutions for evaluation of radiation exposure



Naduparambil Jacob, PhD

OSUCCC – James researchers entered a \$9.42 million federal cooperative agreement that will help them further develop Ohio State's biodosimetry technology to discover noninvasive biomarkers for radiation exposure. Awarded by the Intelligence Advanced Research Projects Activity (IARPA), an organization within the Office of the Director of National Intelligence, and the Army Research Office (ARO),

the agreement aligns with the IARPA's mission “to push the boundaries of science to develop solutions that empower the intelligence community to do its work better and more efficiently for national security.” Principal investigator (PI) **Naduparambil Jacob, PhD**, professor in the Department of Radiation Oncology at Ohio State and member of the Translational Therapeutics Program at the OSUCCC – James, says this work is important because of the possible major health consequences of radiation exposure, including cancer. Being able to determine the amount and range of exposure would help clinicians more quickly and accurately mitigate short- and long-term effects. Read more about this work in the cover story of *Frontiers*.

Federal grants will boost efforts for earlier detection of endometrial and ovarian cancer



Selvendiran Karuppaiyah, PhD

The U.S. Department of Defense (DOD) awarded a pair of grants totaling approximately \$2.65 million to help OSUCCC – James researchers identify cellular biomarkers that could lead to earlier detection of endometrial (uterine) and ovarian cancer. A four-year, \$1.94 million grant from the DOD Peer-Reviewed Cancer Research program will address gaps in early detection and diagnosis of endometrial cancer. A three-

year, \$710,000 grant from the DOD Ovarian Cancer Research Program will enhance efforts for earlier detection of high grade serous ovarian cancer (HGSOC). PI for both is **Selvendiran Karuppaiyah, PhD**, associate professor in the Department of Obstetrics and Gynecology at Ohio State and member of the Translational Therapeutics Program at the OSUCCC – James.

Read about more research and grant highlights at go.osu.edu/2022CancerHighlights.

Pelotonia-funded research and initiatives

Pelotonia Institute for Immuno-Oncology (PIIO)

During its first three years, the PIIO – led by Founding Director **Zihai Li, MD, PhD** – has recruited 22 new faculty and retained one senior faculty leader. Supported by more than 100 investigators, the PIIO strives to be a leader in driving immuno-oncology (IO) breakthroughs. PIIO members' annual funding from grants stands at over \$36 million — including \$18 million from the NCI — and their multi-year direct cost grant funding stands at \$235 million, including \$141 million from the NCI.

In addition, 87 IO clinical trials are being conducted by PIIO researchers, and plans call for opening as many as 130 over the next five years to facilitate a pipeline of novel cancer immunotherapeutics that will be tested in the clinic. Since 2019, PIIO scientists have published 834 peer-reviewed articles in scientific journals and have disclosed over 50 inventions.

For more PIIO highlights, read the 2022 PIIO Annual Report at cancer.osu.edu/2022PIIO.

Idea Grants









Pelotonia-funded Idea Grants enable teams of faculty researchers to gather early data for their innovative ideas so they can later apply for larger grants from external sources such as the National Cancer Institute.

- Idea Grants are two-year awards of up to \$200,000 each.
- In 2022, the OSUCCC – James awarded 20 Idea Grants totaling \$3.38 million.
- Since 2010, the OSUCCC – James has awarded 202 Pelotonia-funded Idea Grants.
- To date, 74 projects that received Pelotonia-funded Idea Grants have received additional funding from external sources.

To read more, visit cancer.osu.edu/IdeaGrants.

Pelotonia Scholars Program

The Pelotonia Scholars Program was started in 2010 to enable Ohio State students in any discipline or level of scholarship to pursue cancer research with faculty mentors. Award recipients represent 47 countries and 34 U.S. states.

654 Scholar Awardees Since 2010	38 Scholar Awardees In 2022
 294 undergraduate students	 16 undergraduate students
 198 graduate students	 10 graduate students
 152 postdoctoral researchers	 8 postdoctoral researchers
 10 medical students	 4 medical students

Recruitment Research Support

Some of the brightest minds in cancer research are recruited to the OSUCCC – James, and Pelotonia dollars often help these researchers continue their work when they arrive.

Through the years, the OSUCCC – James has recruited 270 top scientists who have received Pelotonia funding support, including several in 2022. Among those are these prominent senior-level scientists:

- **Chyke Doubeni, MD, MPH**, as associate director for diversity, equity and inclusion at the OSUCCC – James;
- **Xiaoguang (Margaret) Liu, PhD**, as a member of the OSUCCC – James Center for Cancer Engineering and Translational Therapeutics Program;
- **Daniel Conway, PhD**, as a member of the OSUCCC – James Center for Cancer Engineering and Cancer Biology Program;
- **Regina Crawford, MD**, as director of the Sickle Cell Program in the Division of Hematology;
- **Ting-Yuan (David) Cheng, PhD, MHS**, as a cancer epidemiologist in the Division of Cancer Prevention and Control.

Pelotonia-funded research and initiatives

Statewide Initiatives

The [Ohio Colorectal Cancer Prevention Initiative \(OCCPI\)](#) built a medical-practice network of some 50 hospitals across the state, including community practices, to improve genetic testing for colon cancer patients and their families, and to facilitate patient navigation.

The [Beating Lung Cancer in Ohio \(BLCIO\)](#) study assesses survival and quality of life using genetic testing for advanced-stage lung cancer, coupled with smoking cessation. Leaders of this project, which is supported by \$3 million in Pelotonia funds, anticipate more than 2,000 newly diagnosed patients with stage IV non-small cell lung cancer will enroll in BLCIO via the community hospital network. Enrollees receive free testing for more than 300 genes in their cancer specimens, and physicians who treat them receive expert support for interpreting test results and determining treatments.

The [Ohio Prevention and Treatment of Endometrial Cancer \(OPTEC\)](#) study assesses endometrial cancer patients for Lynch syndrome. OPTEC, supported by \$1.5 million in Pelotonia funds and a five-year NCI grant, has recruited nearly 1,000 women with endometrial (uterine) cancer from partner hospitals in Ohio and screened them for Lynch syndrome (LS) and other inherited genetic conditions linked to greater risk of endometrial, colorectal, stomach and ovarian cancers.

Among OPTEC advances in 2022 was a study published in the journal *Gynecologic Oncology* that determined universal multi-gene panel testing (MGPT) is a practical consideration for patients with newly diagnosed endometrial cancer for cost savings and improved diagnosis of LS and other cancer syndromes that predispose to this disease.

The [Turning the PAGE on Breast Cancer in Ohio](#) project uses a multi-level approach in 12 Ohio counties to provide breast cancer education and facilitate access to risk assessment, genetic counseling and testing, appropriate screening/surveillance, follow up for abnormal tests, and prompt and proper treatment for Black women who are at greater risk of breast cancer mortality.



Instruments of Discovery

In 2022, the OSUCCC – James allocated \$2.5 million to purchase sophisticated equipment for cutting-edge cancer research. Just a few of the acquisitions included: innovative equipment for the OSUCCC – James Medicinal Chemistry Shared Resource – High-Throughput Screening Core; a cell-sorting instrument modernization for the Flow Cytometry Shared Resource; and a state-of-the-art mass spectrometer.

Strategic Research Investments

Designed to have a long-term impact on cancer research and patient care, the OSUCCC – James makes strategic research investments each year that support such large-scale initiatives as:

[Drug Development Institute](#), a biotech-like entity that helps rapidly translate Ohio State's innovative research to promising treatments for patients with cancer;

[Digital Pathology](#), the management of data and information generated by digitized specimen slides of blood, tissues and other biological samples;


[Total Cancer Care® \(TCC\)](#) protocol, through which the OSUCCC – James has enrolled more than 66,000 patients for voluntarily sharing de-identified clinical data that moves cancer research forward and personalizes cancer care.

[Center for Cancer Engineering](#), a collaboration to design, develop and integrate innovative engineering technologies and data-analytics approaches with cancer biology, biomechanics and fundamental science, with the goal of enhancing cancer prevention, detection, diagnosis and treatment.

Read more at go.osu.edu/2022PelotoniaImpact.

Building the OSUCCC – James Center for Cancer Engineering (CCE):

The Skardal Biofabrication Lab



Drs. Dedhia and Skardal


The research program in the Skardal Biofabrication Lab, led by **Aleksander Skardal, PhD**, focuses on the design and implementation of extracellular, matrix-inspired hydrogel biomaterials for the biofabrication of tissue and tumor organoids, organ-on-a-chip systems and cancer-on-a-chip systems for drug screening, disease modeling and personalized medicine.

The Skardal Lab is a central feature of the CCE, and a 2020 Pelotonia Idea Grant helped these scientists establish a foothold and move their research forward. Many of the initial collaborations that have started since the lab arrived at Ohio State have accelerated significantly and yielded strong results in 2022.


The team deployed its organoid-based metastasis-on-a-chip platform within both thyroid cancer (with **Matthew Ringel, MD**) and adrenocortical carcinoma (with **Priya Dedhia, MD, PhD**). The organ-on-a-chip model of the pre-metastatic niche made significant progress toward perhaps one of the first fully realized *in vitro* models of the pre-metastatic niche in colorectal cancer.

In addition, they continued or initiated projects in immuno-oncology in which cells of the immune system are integrated into the lab's bioengineered model systems either as functional components or as therapeutic interventions, as well as a bioengineered blood-brain model to better study glioblastoma, an aggressive form of brain cancer. They also continued their work with biofabrication and bioprinting and implementation of patient-derived tumor organoid constructs in several cancers.


Ohio State's Organoid Technology Program (founded by Drs. Skardal and Dedhia in 2020) was expanded to over 30 faculty members and began including postdocs and other learners as well as staff. These and other efforts resulted in 11 publications, and the lab team secured extramural funding in the form of one U.S. Department of Defense award, three NIH awards and one industry-sponsored award.



A sample of a metastasis-on-a-chip created in the Skardal Lab.



A patient-derived tumor organoid generated from a human sarcoma patient's tumor. The green indicates living cells, while the red indicates dead cell nuclei.



3D in vitro blood-brain barrier-on-a-chip, biofabricated in a microfluidic device to study glioblastoma heterogeneity, invasion and the crosstalk between blood vessels in the brain and the tumor.

Recent recruits

Some of the brightest minds in cancer research and care joined the OSUCCC – James in 2022. Among them are these prominent senior-level recruits:



Ting-Yuan (David) Cheng, PhD, MHS, MS

Ting-Yuan (David) Cheng, PhD, MHS, MS, is a cancer epidemiologist who was recruited from the University of Florida as an associate professor in the Division of Cancer Prevention and Control. His research focuses on understanding cancer etiology and factors that affect cancer outcomes among different racial and ethnic outcomes. He earned his PhD at the University of Washington.



Regina Crawford, MD

and patient care. At Duke, Dr. Crawford was a benign hematologist, therapeutic apheresis specialist and sickle cell specialist who led the Duke Adult Sickle Cell Program. She earned her MD at the University of Cincinnati, served her internship and residency at the University of Texas Medical Branch in Galveston, and completed her fellowship in Hematology-Oncology at Ohio State in 2007.

Regina Crawford, MD, was recruited from Duke University Medical Center to become director of the Sickle Cell Program and clinical associate professor in the Division of Hematology at Ohio State. In this role, she oversees all clinical and operational aspects of the Sickle Cell Program while maintaining the division's three-part mission of teaching, research



Daniel Conway, PhD

fluorescent-based imaging approaches to study cell mechanics, with a focus on resolving mechanical forces at cell-cell adhesions and the nucleus. His current research examines how mechanical forces at cell-cell adhesions and the nuclear LINC complex regulate epithelial homeostasis. He earned his PhD in the joint Biomedical Engineering program between Georgia Institute of Technology and Emory University.


Daniel Conway, PhD, came to Ohio State from Virginia Commonwealth University to serve as a professor in the College of Engineering, Department of Biomedical Engineering, and as a member of the Cancer Biology Program at the OSUCCC – James, where he also is in the Center for Cancer Engineering. His research is focused on developing



Chyke Doubeni, MD, MPH

Medicine. Dr. Doubeni came to Ohio State from the Mayo Clinic, where he directed the Mayo Clinic Center for Health Equity and Community Engagement Research.

Chyke Doubeni, MD, MPH, became associate director for diversity, equity and inclusion at the OSUCCC – James. He also serves as chief health equity officer and leader of the Office of Health Equity, Diversity and Inclusion at the Ohio State Wexner Medical Center, and he holds a faculty appointment in the Department of Family and Community Medicine at the Ohio State College of



Xiaoguang (Margaret) Liu, PhD

Xiaoguang (Margaret) Liu, PhD, was recruited from the University of Alabama at Birmingham as professor in the College of Engineering, Department of Chemical and Biomolecular Engineering, and as a member of the Translational Therapeutics Program at the OSUCCC – James, where she also is in the Center for Cancer Engineering. Her research focuses on targeted

anticancer therapy development, biomanufacturing and evaluations. Dr. Liu worked in the biopharmaceutical and biotechnology industries for seven years before joining academia, where she has over 10 years of research experience. She earned her PhD at Ohio State in 2005.



Peng Wang, MD, PhD

Peng Wang, MD, PhD, was recruited to Ohio State from the University of Kentucky Markey Cancer Center as an associate professor in the Division of Medical Oncology. Dr. Wang specializes in treating genitourinary (GU) cancers, including prostate, bladder, kidney and testicular cancers. He also is in the Translational Therapeutics Program at the OSUCCC – James, where his research


is focused on developing predictive biomarkers for chemo and immunotherapy in bladder and kidney cancers, and on epidemiology and disparities in GU cancers. Dr. Wang earned his MD and PhD at Tongji Medical University in Shanghai, China, and he completed his fellowship training in hematology and oncology at the University of Pittsburgh.



Corrin Steinhauer, DNP, RN, NEA-BC, CPPS

Corrin Steinhauer, DNP, RN, NEA-BC, CPPS, became chief nursing officer at The James in 2022. She succeeded **Kris Kipp, MSN, RN**, who had served as chief nursing officer since 2013 and remains executive director of clinical services. Dr. Steinhauer came to The James from the University of Chicago Medicine Ingalls Memorial Hospital, where she was vice president of

patient care services and chief nursing officer. She has a strong academic medical center background and proven experience in leading a cancer service line. She earned a BSN and an MS in nursing administration from Purdue University, and a DNP in systems leadership from Rush University in Chicago.



Institutional achievements

OSUCCC – James gains third Magnet® recognition and nine exemplars for nursing care

For the third consecutive time, the OSUCCC – James achieved Magnet® recognition from the American Nurses Credentialing Center. The renewed Magnet® status, which will extend for four years, was accompanied by nine exemplars for nursing care. The Magnet Recognition Program® recognizes health care organizations for quality patient care, nursing excellence and innovations in professional nursing practice. The OSUCCC – James first achieved Magnet® status in 2013 and regained it in 2018.

OSUCCC – James earns more Press Ganey® awards for patient care excellence

The OSUCCC – James earned three national awards for excellence in patient care delivery from Press Ganey, a health care performance-improvement organization that works with more than 41,000 facilities.

For the **seventh consecutive year**, the OSUCCC – James received the **Press Ganey Guardian of Excellence Award® for Patient Experience** for sustaining excellence in patient experience over a single year.

The institution also received its **fourth straight Press Ganey Pinnacle of Excellence Award® for Patient Experience in Inpatient Care** (with regard to the non-Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) sections of the hospital's inpatient survey) for maintaining excellence over consecutive years.

In addition, it received its **third straight Press Ganey Pinnacle of Excellence Award® for Patient Experience in HCAHPS** for maintaining excellence over consecutive years.



Pelotonia 2022 raises nearly \$22 million for cancer research

Riders, Challengers, Volunteers and Donors in Pelotonia 2022 – the annual cycling event that raises millions of dollars for cancer research at Ohio State – generated \$21,815,484 and boosted the 14-year total to more than \$258.65 million, all of which goes to research at the OSUCCC – James thanks to the event's Funding Partners. Pelotonia Ride Weekend, which took place Aug. 5-7 on routes between Columbus and Gambier, Ohio, involved 11,141 participants, including more than 6,400 Riders from 45 states and five countries. In addition, more than 3,365 Challenger goals were met in 2022, and the over 2,700 Volunteers logged more than 15,200 hours.

The James & Wexner Medical Center recognized as LGBTQ+ HEI leaders

The James and the Ohio State Wexner Medical Center are among 17 health care entities in Ohio that were recognized by the Human Rights Campaign Foundation as 2022 LGBTQ+ Healthcare Equality Index (HEI) Leaders. The HEI is a national LGBTQ+ benchmarking tool that evaluates health care facilities' policies and practices related to the equity and inclusion of their LGBTQ+ patients, visitors and employees. The HEI evaluates more than 1,700 health care facilities nationwide.



The James is nationally ranked by *U.S. News* for 24th consecutive year

U.S. News & World Report listed the James Cancer Hospital and Solove Research Institute among America's Best Hospitals for cancer care for the 24th straight year, ranking it 24th for 2022-23, an improvement over the 2021-22 ranking at No. 27. The James first appeared on the *U.S. News* list in 1999, less than a decade after opening in 1990, and has remained there since. Cancer is among nine health care specialties at the Ohio State Wexner Medical Center that *U.S. News* listed among America's best in the 2022-23 rankings. Additionally, the medical center is the No. 1 ranked adult hospital in Columbus and second in Ohio.

Pelotonia is recipient of AACI Champions for Cure Award

Pelotonia received the 2022 Association of American Cancer Institutes (AACI) Champions for Cure Award, which recognizes one or more people who, through direct financial support of an AACI cancer center, demonstrate exceptional leadership in advancing cancer research and care and in inspiring others to do the same. Since 2009, Pelotonia has raised more than \$258.65 million for the OSUCCC – James, all of which has directly supported projects that address many areas of cancer research and help change the landscape of cancer care.

New or renewed institutional designations, certifications and accreditations

The OSUCCC – James **Acute Leukemia Program** received a disease-specific care re-certification from **The Joint Commission**, the nation's top hospital-ranking organization. The Acute Leukemia Program is one of only three in the United States to have earned this advanced-level certification. It initially received Joint Commission certification in 2020. Joint Commission disease-specific certification means the program complies with the highest national standards for safety and quality of care and is committed to continually improving patient care.

To read more about additional awards and honors that OSUCCC – James teams and individuals received in 2022, visit go.osu.edu/2022CancerAwards.

New or renewed institutional designations, certifications and accreditations

The International Cardio-Oncology Society (IC-OS) designated **Ohio State's Cardio-Oncology Program as a Center of Excellence (Gold Standard)** for three years in recognition of the program's outstanding professional contributions to cardio-oncology. The IC-OS defines a Center of Excellence as a program that is "assembled to supply an exceptionally high concentration of expertise and related resources centered on a particular area of medicine, delivering associated care in a comprehensive, interdisciplinary fashion to afford the best patient outcomes." The Cardio-Oncology Program is led by Director **Daniel Addison, MD**, associate professor in Division of Cardio-Vascular Medicine at Ohio State and member of the Cancer Control Program at the OSUCCC – James.

The Blood and Marrow Transplant (BMT) Unit at the OSUCCC – James was recognized for exceptional patient care and professional nursing practice with a **three-year Silver Beacon Award for Excellence from the American Association of Critical-Care Nurses (AACN)**. This award honors hospital units that employ evidence-based practices to improve patient and family outcomes, and that exemplify excellence in professional practice and patient care. It's the third Beacon Award of Excellence Award for the unit, which previously received a bronze award in 2015 and a gold award in 2018.

The **Advanced Practice Provider (APP) Fellowship Program at Ohio State** received a four-year reaccreditation from the American Nurses Credentialing Center's (ANCC) **Practice Transition Accreditation Program® (PTAP)**. PTAP is the premier accreditation for fellowship programs that transition advanced practice registered nurses (APRNs) into new practice settings. The James Oncology and Critical Care Advanced Practice Fellowship was previously accredited in 2016 and 2019. In 2019, the university's APP fellowship programs combined into one Health System Fellowship. With this latest reaccreditation, the university was accredited as one Health System with the addition of a Primary Care Fellowship. The Ohio State University Health System APP Fellowship is one of only 26 accredited PTAP APRN programs.

The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER

The Ohio State University
Comprehensive Cancer Center –
Arthur G. James Cancer Hospital
and Richard J. Solove Research Institute
460 W. 10th Ave.
Columbus, Ohio 43210

cancer.osu.edu

Non-Profit
U.S. Postage
P A I D
Columbus, OH
Permit No. 711



PELTONIA®

**REGISTRATION
IS OPEN**

**RIDE
WEEKEND**

AUGUST 5-6

**GRAVEL
DAY**

SEPTEMBER 30

**PELTONIA.ORG/
REGISTER**

JOIN THE PELTONIA COMMUNITY AS A
RIDER, VOLUNTEER, OR CHALLENGER!

